Cargando…

Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report

Patient: Male, 37-year-old Final Diagnosis: Immune-mediated myocarditis • pulmonary vasculitis • myositis • thrombocytopenia Symptoms: Episode of hemoptysis with blood less than 100 ml • one-day history of sudden onset severe shortness of breath associated with orthopnea, dry cough and excessive swe...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Rasbi, Sara, Al-Mqbali, Juhaina Salim, Al-Farsi, Rajaa, Shukaili, Moza Ali Al, Al-Riyami, Maryam H., Falahi, Zubaida Al, Farhan, Hatem Al, Al Alawi, Abdullah M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865877/
https://www.ncbi.nlm.nih.gov/pubmed/35173141
http://dx.doi.org/10.12659/AJCR.934399
_version_ 1784655713087258624
author Al-Rasbi, Sara
Al-Mqbali, Juhaina Salim
Al-Farsi, Rajaa
Shukaili, Moza Ali Al
Al-Riyami, Maryam H.
Falahi, Zubaida Al
Farhan, Hatem Al
Al Alawi, Abdullah M.
author_facet Al-Rasbi, Sara
Al-Mqbali, Juhaina Salim
Al-Farsi, Rajaa
Shukaili, Moza Ali Al
Al-Riyami, Maryam H.
Falahi, Zubaida Al
Farhan, Hatem Al
Al Alawi, Abdullah M.
author_sort Al-Rasbi, Sara
collection PubMed
description Patient: Male, 37-year-old Final Diagnosis: Immune-mediated myocarditis • pulmonary vasculitis • myositis • thrombocytopenia Symptoms: Episode of hemoptysis with blood less than 100 ml • one-day history of sudden onset severe shortness of breath associated with orthopnea, dry cough and excessive sweating • reducing sensation to fine touch and temperature at the entire left upper limb • three-days history of back pain Medication: — Clinical Procedure: — Specialty: General and Internal Medicine OBJECTIVE: Unusual clinical course BACKGROUND: The COVID-19 pandemic is a current global crisis, and there are hundreds of millions of individuals being vaccinated worldwide. At present, there have been few reports of COVID-19 vaccine-induced autoimmune processes manifested as myositis, thrombocytopenia, and myocarditis. CASE REPORT: A 37-year-old man presented to the Emergency Department (ED) with a 3-day history of back pain and a 1-day history of left upper limb swelling with paresthesia and shortness of breath, 12-days after receiving the first dose of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine. He was diagnosed with severe myositis complicated with rhabdomyolysis and non-oliguric acute kidney injury, thrombocytopenia, myocarditis with pulmonary edema, and pulmonary hemorrhage. Screens for potential toxic, infectious, paraneoplastic, and autoimmune disorders were unremarkable. The patient was treated with a 5-day course of intravenous methylprednisolone and intravenous immunoglobulin, with a good response. He was hospitalized for 16 days and discharged home on a tapering dose of oral prednisolone for 6 weeks. CONCLUSIONS: The case describes a possible link between Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine and immune-mediated myocarditis, pulmonary vasculitis, myositis, and thrombocytopenia. However, further data are required to confirm such an association.
format Online
Article
Text
id pubmed-8865877
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-88658772022-03-17 Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report Al-Rasbi, Sara Al-Mqbali, Juhaina Salim Al-Farsi, Rajaa Shukaili, Moza Ali Al Al-Riyami, Maryam H. Falahi, Zubaida Al Farhan, Hatem Al Al Alawi, Abdullah M. Am J Case Rep Articles Patient: Male, 37-year-old Final Diagnosis: Immune-mediated myocarditis • pulmonary vasculitis • myositis • thrombocytopenia Symptoms: Episode of hemoptysis with blood less than 100 ml • one-day history of sudden onset severe shortness of breath associated with orthopnea, dry cough and excessive sweating • reducing sensation to fine touch and temperature at the entire left upper limb • three-days history of back pain Medication: — Clinical Procedure: — Specialty: General and Internal Medicine OBJECTIVE: Unusual clinical course BACKGROUND: The COVID-19 pandemic is a current global crisis, and there are hundreds of millions of individuals being vaccinated worldwide. At present, there have been few reports of COVID-19 vaccine-induced autoimmune processes manifested as myositis, thrombocytopenia, and myocarditis. CASE REPORT: A 37-year-old man presented to the Emergency Department (ED) with a 3-day history of back pain and a 1-day history of left upper limb swelling with paresthesia and shortness of breath, 12-days after receiving the first dose of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine. He was diagnosed with severe myositis complicated with rhabdomyolysis and non-oliguric acute kidney injury, thrombocytopenia, myocarditis with pulmonary edema, and pulmonary hemorrhage. Screens for potential toxic, infectious, paraneoplastic, and autoimmune disorders were unremarkable. The patient was treated with a 5-day course of intravenous methylprednisolone and intravenous immunoglobulin, with a good response. He was hospitalized for 16 days and discharged home on a tapering dose of oral prednisolone for 6 weeks. CONCLUSIONS: The case describes a possible link between Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine and immune-mediated myocarditis, pulmonary vasculitis, myositis, and thrombocytopenia. However, further data are required to confirm such an association. International Scientific Literature, Inc. 2022-02-17 /pmc/articles/PMC8865877/ /pubmed/35173141 http://dx.doi.org/10.12659/AJCR.934399 Text en © Am J Case Rep, 2022 https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Articles
Al-Rasbi, Sara
Al-Mqbali, Juhaina Salim
Al-Farsi, Rajaa
Shukaili, Moza Ali Al
Al-Riyami, Maryam H.
Falahi, Zubaida Al
Farhan, Hatem Al
Al Alawi, Abdullah M.
Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report
title Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report
title_full Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report
title_fullStr Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report
title_full_unstemmed Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report
title_short Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report
title_sort myocarditis, pulmonary hemorrhage, and extensive myositis with rhabdomyolysis 12 days after first dose of pfizer-biontech bnt162b2 mrna covid-19 vaccine: a case report
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865877/
https://www.ncbi.nlm.nih.gov/pubmed/35173141
http://dx.doi.org/10.12659/AJCR.934399
work_keys_str_mv AT alrasbisara myocarditispulmonaryhemorrhageandextensivemyositiswithrhabdomyolysis12daysafterfirstdoseofpfizerbiontechbnt162b2mrnacovid19vaccineacasereport
AT almqbalijuhainasalim myocarditispulmonaryhemorrhageandextensivemyositiswithrhabdomyolysis12daysafterfirstdoseofpfizerbiontechbnt162b2mrnacovid19vaccineacasereport
AT alfarsirajaa myocarditispulmonaryhemorrhageandextensivemyositiswithrhabdomyolysis12daysafterfirstdoseofpfizerbiontechbnt162b2mrnacovid19vaccineacasereport
AT shukailimozaalial myocarditispulmonaryhemorrhageandextensivemyositiswithrhabdomyolysis12daysafterfirstdoseofpfizerbiontechbnt162b2mrnacovid19vaccineacasereport
AT alriyamimaryamh myocarditispulmonaryhemorrhageandextensivemyositiswithrhabdomyolysis12daysafterfirstdoseofpfizerbiontechbnt162b2mrnacovid19vaccineacasereport
AT falahizubaidaal myocarditispulmonaryhemorrhageandextensivemyositiswithrhabdomyolysis12daysafterfirstdoseofpfizerbiontechbnt162b2mrnacovid19vaccineacasereport
AT farhanhatemal myocarditispulmonaryhemorrhageandextensivemyositiswithrhabdomyolysis12daysafterfirstdoseofpfizerbiontechbnt162b2mrnacovid19vaccineacasereport
AT alalawiabdullahm myocarditispulmonaryhemorrhageandextensivemyositiswithrhabdomyolysis12daysafterfirstdoseofpfizerbiontechbnt162b2mrnacovid19vaccineacasereport